Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generics: Capitol Hill’s Super “Pay For”

This article was originally published in The Pink Sheet Daily

Executive Summary

As the user fee legislation continues its remarkably tranquil journey with a unanimous vote in the House Energy & Commerce Committee, tweaks to the ANDA review process have helped smooth some of the rough edges.

You may also be interested in...



GPhA’s Deficit Reduction Proposals Focus On Medicare Low-Income Subsidy, REMS Policies

In letters to congressional leaders, generic drug trade group outlines six proposals that it says would save the government billions of dollars and lessen the impact of sequestration cuts.

Pallone, Pitts Committed To Cosmetics Legislation In “This Congress”

During a markup of an FDA user-fee bill, legislators from both sides of the aisle affirmed their intent to tackle cosmetics regulation in a separate, stand-alone bill later this year. The user-fee bill omitted a section that was in place previously to implement cosmetics user fees.

User Fee Legislation Revs Through Senate Mark-up, But House Bill Goes Back Into The Shop

Senate health committee defers action on several potentially contentious issues, with members hoping to resolve differences over FDA’s authorities on imports, shortages, foreign data and track-and-trace before the bill goes to the floor, possibly in May. Meanwhile, the House postpones its mark-up in an effort to craft a more bipartisan bill, and now will try to push the user fee package to the floor during an upcoming four-day marathon session.

Related Content

Topics

UsernamePublicRestriction

Register

PS074099

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel